Public Release:  Promising new finding for therapies to treat persistent seizures in epileptic patients

LA BioMed researcher says study identified new potential site for medications to target

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

IMAGE

IMAGE: Photos depict NMDA receptors moving to the neuron surface during status epilepticus (SE), persistent seizures. The NMDA receptors are in red (NR1), and the cell surface marker is in green... view more

Credit: Dr. David E. Nayor

LOS ANGELES (Jan. 16, 2013) - In a promising finding for epileptic patients suffering from persistent seizures known as status epilepticus, researchers reported today that new medication could help halt these devastating seizures. To do so, it would have to work directly to antagonize NMDA receptors, the predominant molecular device for controlling synaptic activity and memory function in the brain.

"Despite the development of new medications to prevent seizures, status epilepticus remains a life-threatening condition that can cause extensive brain damage in the patients that survive these persistent seizures," said David E. Naylor, MD, PhD, a lead researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and corresponding author of the new study. "Our research holds promise for the development of new therapies to treat this devastating condition because we have found a potential new target for medical intervention that should bolster the current standard therapies to treat the acute seizures. It may also prevent the long-term adverse effects of persistent seizure activity on the brain."

The research, reported online in the Neurology of Disease journal, used animal models to assess cellular activity in the brain during persistent seizures. It found that the seizure activity seemed to force the NMDA receptors from the interior to the surface of nerve cells causing their activity to increase by approximately 38%.

"The increased presence of the NMDA receptors on the cell surface during these seizures may explain the successful use of NMDA antagonists - medication that inhibits the activity of the NMDA receptors in the brain - in the latter stages of a seizure, long after other medications have stopped working," said Dr. Naylor. "We concluded that medications that suppress the activity of the NMDA receptors, in conjunction with other medications, may be successful in stopping persistent seizures. Further research is, of course, needed."

###

In addition to Dr. Naylor, the researchers who participated in the study were Drs. Hantao Liu at the Veterans Administration Greater Los Angeles County Healthcare System's Department of Neurology and Jerome Niquet and Claude G. Wasterlain of the David Geffen School of Medicine at the University of California, Los Angeles Department of Neurology. The research was funded by LA BioMed and a Veterans Administration Career Development Award. The study may be viewed online at http://www.sciencedirect.com/science/article/pii/S0969996113000065

About LA BioMed

Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and therapies for chronic diseases, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit www.labiomed.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.